Compare · DXCM vs SKIN
DXCM vs SKIN
Side-by-side comparison of DexCom Inc. (DXCM) and SkinHealth Systems Inc. (SKIN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SKIN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 270.5x SKIN ($109.4M).
- Over the past year, DXCM is down 8.6% and SKIN is down 47.1% - DXCM leads by 38.5 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 3 for SKIN).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- SkinHealth Systems Inc.
- Price
- $76.65-1.74%
- $0.84+2.13%
- Market cap
- $29.58B
- $109.4M
- 1M return
- +4.76%
- +27.39%
- 1Y return
- -8.64%
- -47.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
SkinHealth Systems Inc.
Edge Systems, LLC designs, develops, manufactures, markets, and sells aesthetic technologies and products. It offers hydradermabrasion system that enhances the skin to cleanse, exfoliate, extract, and hydrate simultaneously; Hydraglucan Intense Hydration Booster, a customization for the HydraFacial treatment exfoliates the skin by improving cell renewal and delivers ingredients, including hyaluronic acid, glucan, and betaine to hydrate the skin and provide anti-aging benefits; HydraFacial Daily Essentials, which provides detoxification, rejuvenation, and protection of skin; crystal microdermabrasion systems; and light emitting diode systems. The company also provides HydraFacial CONNECT platform, a three-level industry certification program that will advance aesthetic professionals' skills and give them recognition, respect, and rewards; and system surgical smoke evacuators that vacuums the plume created by laser and electrocautery treatments, such as hair removal, tattoo removal, erbium, and veterinary procedures. Its system surgical smoke evacuators are used by hospitals, plastic surgeons, cosmetic surgeons, OB/GYN, veterinarians, and others. In addition, it offers marketing support services. Its products are distributed worldwide through its sales network. The company was founded in 1997 and is based in Signal Hill, California with a location in Long Beach, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest SKIN
- Amendment: SEC Form SCHEDULE 13G/A filed by SkinHealth Systems Inc.
- SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
- SkinHealth Systems Inc. filed SEC Form 8-K: Other Events
- SkinHealth Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Hydrafacial Introduces HydraScalp® with Keravive™ as Next Evolution in Scalp Health
- Amendment: SkinHealth Systems Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SkinHealth Systems Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by SkinHealth Systems Inc.
- SkinHealth Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SkinHealth Systems Reports First Quarter 2026 Financial Results